UNSPSC 51162720: Letosteine

This classification denotes a mucolytic agent with the molecular formula C10H17NO4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 6MVF9U95DW, chemically known as 4-thiazolidinecarboxylic acid, 2-(2-((2-ethoxy-2-oxoethyl)thio)ethyl)- but more generally known as letosteine, which bears US NIH Compound Identifier 68707. European Medicines Agency schedules Letosteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08442MIG. The term LETOSTEINE is an International Non-Proprietary Name.

UNSPSC 51162720 Letosteine, a Commodity code, covers pharmaceutical and medical products procured by state and local governments for healthcare delivery to incarcerated populations and community health initiatives. The recent solicitations under this code reflect purchases of parenteral nutrition solutions, intravenous products, naloxone, and drug deactivation systems — pharmaceuticals and medical supplies distributed through correctional healthcare systems and public health departments rather than retail or commercial channels. Issuing bodies include state departments of corrections and county health authorities, each managing supply chains for specialized populations with urgent delivery and documentation requirements.

The Washington State Department of Corrections posted RFQ RFQQK13020 on September 8, 2026, requesting parenteral products and services (parenteral nutrition solutions, IV solutions, and controlled substances) for delivery to eight correctional facilities across three regions, with a response deadline of October 7, 2026 and a pre-bid conference on September 23, 2026; the initial contract runs November 26, 2026 through June 30, 2030, with DOC anticipated to award up to three bidders per region and set-aside targets for small, minority-owned, women-owned, and veteran-owned businesses. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building and a two-year initial term with one-year renewal option. Geographic activity is concentrated in the Pacific Northwest and Southeast, with Washington State and Florida both showing recent procurement activity under the code.